{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:36:00Z","timestamp":1771331760676,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81230014"],"award-info":[{"award-number":["81230014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81520108002"],"award-info":[{"award-number":["81520108002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470341"],"award-info":[{"award-number":["81470341"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41409-020-01060-5","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T21:40:24Z","timestamp":1600378824000},"page":"570-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy"],"prefix":"10.1038","volume":"56","author":[{"given":"Ruimin","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4102-547X","authenticated-orcid":false,"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"1060_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473\u20134.","journal-title":"Science"},{"key":"1060_CR2","first-page":"129","volume":"378","author":"MB Oldstone","year":"2014","unstructured":"Oldstone MB, Rosen H. Cytokine storm plays a direct role in the morbidity and mortality from influenza virus infection and is chemically treatable with a single sphingosine-1-phosphate agonist molecule. Curr Top Microbiol Immunol. 2014;378:129\u201347.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188\u201395.","journal-title":"Blood"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1172\/JCI137647","volume":"130","author":"SF Pedersen","year":"2020","unstructured":"Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130:2202\u20135.","journal-title":"J Clin Invest"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.","journal-title":"J Immunother Cancer"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","volume":"3","author":"L Y\u00e1\u00f1ez","year":"2019","unstructured":"Y\u00e1\u00f1ez L, S\u00e1nchez-Escamilla M, Perales MA. CAR T cell toxicity: current management and future directions. Hemasphere. 2019;3:e186.","journal-title":"Hemasphere"},{"key":"1060_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119\u201322.","journal-title":"Cancer J"},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019;25:1341\u201355.","journal-title":"Nat Med"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute; ymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","journal-title":"Blood"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958\u201369.","journal-title":"Nat Rev Immunol"},{"key":"1060_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz017","author":"BD Hunter","year":"2019","unstructured":"Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst. 2019. https:\/\/doi.org\/10.1093\/jnci\/djz017.","journal-title":"J Natl Cancer Inst"},{"key":"1060_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","volume":"9","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9:761\u201370.","journal-title":"Emerg Microbes Infect"},{"key":"1060_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1158\/2159-8290.CD-20-0473","volume":"10","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, June CH. Harnessing CAR T-cell insights to develop treatments for hyperinflammatory responses in patients with COVID-19. Cancer Discov. 2020;10:775\u20138.","journal-title":"Cancer Discov"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"1060_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13091.","author":"G Pascarella","year":"2020","unstructured":"Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020. https:\/\/doi.org\/10.1111\/joim.13091.","journal-title":"J Intern Med"},{"key":"1060_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100707.","author":"JT England","year":"2020","unstructured":"England JT, Abdulla A, Biggs CM, Lee AYY, Hay KA, Hoiland RL, et al. Weathering the COVID-19 storm: lessons from hematologic cytokine syndromes. Blood Rev. 2020. https:\/\/doi.org\/10.1016\/j.blre.2020.100707.","journal-title":"Blood Rev"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"1060_CR21","unstructured":"Diagnosis and Treatment Plan of COVID-19 (5th Trial Edtion, Revised). Chin J Integr Med. 2020;40:136\u20138."},{"key":"1060_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0; 2017.11.27:51."},{"key":"1060_CR23","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1073\/pnas.0711241105","volume":"105","author":"S Haga","year":"2008","unstructured":"Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, et al. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci USA. 2008;105:7809\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1060_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2020.102567","volume":"19","author":"Y Jamilloux","year":"2020","unstructured":"Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, Jammal T. El, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19:1\u201313.","journal-title":"Autoimmun Rev"},{"key":"1060_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/mi.2017.71","volume":"11","author":"MM Leiva-Ju\u00e1rez","year":"2018","unstructured":"Leiva-Ju\u00e1rez MM, Kolls JK, Evans SE. Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense. Mucosal Immunol. 2018;11:21\u201334.","journal-title":"Mucosal Immunol"},{"key":"1060_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00696-18","volume":"9","author":"CT Kirkpatrick","year":"2018","unstructured":"Kirkpatrick CT, Wang Y, Leiva Juarez MM, Shivshankar P, Pantale\u00f3n Garc\u00eda J, Plumer AK, et al. Inducible lung epithelial resistance requires multisource reactive oxygen species generation to protect against viral infections. mBio 2018;9:1\u201318.","journal-title":"mBio"},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827.","journal-title":"Front Immunol"},{"key":"1060_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.012.","author":"B Xu","year":"2020","unstructured":"Xu B, Fan CY, Wang AL, Zou YL, Yu YH, He C, et al. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China. J Infect. 2020. https:\/\/doi.org\/10.1016\/j.jinf.2020.04.012.","journal-title":"J Infect"},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor t cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23:943\u20137.","journal-title":"Oncologist"},{"key":"1060_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/bjh.15644","volume":"183","author":"KA Hay","year":"2018","unstructured":"Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. Br J Haematol. 2018;183:364\u201374.","journal-title":"Br J Haematol"},{"key":"1060_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1060_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40261-020-00917-3","volume":"40","author":"S Zhang","year":"2020","unstructured":"Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig. 2020;40:511\u20138.","journal-title":"Clin Drug Investig"},{"key":"1060_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2020.102567","volume":"19","author":"Y Jamilloux","year":"2020","unstructured":"Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19:1\u201313.","journal-title":"Autoimmun Rev"},{"key":"1060_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-016-0336-6","volume":"10","author":"JE McDermott","year":"2016","unstructured":"McDermott JE, Mitchell HD, Gralinski LE, Eisfeld AJ, Josset L, Bankhead A 3rd, et al. The effect of inhibition of PP1 and TNF\u03b1 signaling on pathogenesis of SARS coronavirus. BMC Syst Biol. 2016;10:93.","journal-title":"BMC Syst Biol"},{"key":"1060_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.062.","author":"Z Yang","year":"2020","unstructured":"Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.062.","journal-title":"J Infect"},{"key":"1060_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.tem.2012.11.005","volume":"24","author":"JM Busillo","year":"2013","unstructured":"Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends Endocrinol Metab. 2013;24:109\u201319.","journal-title":"Trends Endocrinol Metab"},{"key":"1060_CR37","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2006-10-048215","volume":"109","author":"S Bhattacharyya","year":"2007","unstructured":"Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood. 2007;109:4313\u20139.","journal-title":"Blood"},{"key":"1060_CR38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1097\/CM9.0000000000000791","volume":"133","author":"YY Qin","year":"2020","unstructured":"Qin YY, Zhou YH, Lu YQ, Sun F, Yang S, Harypursat V, et al. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial. Chin Med J. 2020;133:1080\u20136.","journal-title":"Chin Med J"},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/ijms20112754","volume":"20","author":"C Boni","year":"2019","unstructured":"Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, et al. HBV immune-therapy: from molecular mechanisms to clinical applications. Int J Mol Sci. 2019;20:2754.","journal-title":"Int J Mol Sci"},{"key":"1060_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.retram.2020.06.003","volume":"68","author":"Y Hu","year":"2020","unstructured":"Y Hu, E Tan Su Yin, Y Yang, H Wu, G Wei, J Su, et al. CAR T-cell treatment during the COVID-19 pandemic: management strategies and challenges. Curr Res Transl Med. 2020, 68:111\u20138.","journal-title":"Curr Res Transl Med"},{"key":"1060_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-SITC2020.0001","volume":"8","author":"J Wei","year":"2020","unstructured":"Wei J, Zhao J, Han M, Meng F, Zhou J. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity. J Immunother Cancer. 2020;8:1\u20138.","journal-title":"J Immunother Cancer"},{"key":"1060_CR42","unstructured":"ASTCT INTERIM PATIENT GUIDELINES APRIL 20, 2020. Available from: https:\/\/www.astct.org\/viewdocument\/astct-interim-patient-guidelines-ap?CommunityKey=d3949d84-3440-45f4-814290ea05adb0e5&tab=librarydocuments."}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01060-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01060-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T23:18:47Z","timestamp":1631834327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-020-01060-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1038\/s41409-020-01060-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"25 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}